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Abstract
Background: We designed a single-arm, open-label phase II trial of everolimus in PIK3CA amplification/mutation
and/or PTEN loss patients with advanced solid tumors refractory to standard therapy (#NCT02449538).
Methods: Everolimus was administered orally at a daily dose of 10 mg continuously (28-day cycles). Treatment was
continued until progression of the disease or intolerable toxicity was observed. Based on Simon’s two-stage optimal
design, 10 patients were treated with everolimus during the first stage.
Results: The median age of the patients was 55.5 years (range, 42–72), and the median Eastern Cooperative Oncology
Group (ECOG) performance status (PS) was 2 (range, 1–2). Most of the patients (50.0%) had gastric cancer (GC) as the
site of their primary tumor followed by colorectal cancer (CRC), pancreatic cancer, and cholangiocarcinoma. Patients
received everolimus as a third-line (3 patients), fourth-line (4 patients), fifth-line (1 patient) or sixth-line (2 patients)
treatment. Complete or partial responses were not observed in any of the patients. Four patients showed stable
disease, resulting in a disease control rate of 40%. The median PFS was 1.6 months (95% CI, 0.8–2.4 months). Grade 3 or
greater hematologic/non-hematologic toxicity was not observed. Grade 2 diarrhea and stomatitis were reported in one
patient each. There were no treatment-related deaths. There was less than one response out of the 10 initial patients
during the first stage, and the study did not progress to the second stage.
Conclusions: The study did not meet its primary objective of demonstrating the anti-tumor activity of everolimus in
PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.
Further investigation using other genomic candidates and new-generation mTOR inhibitors is warranted in patients
with treatment-refractory cancer.
Trial registration: #NCT02449538, April 2015.
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Background
Clinical development process of molecularly targeted
agents for cancer and is similar to that of cytotoxic
agents are pretty similar, targeting tumor location and
histology [1–3]. Irrespective of different tumor types and
histology, Mmost molecular alterations exist irrespective
of different tumor types and histologies, although the
incidence can varyies [4]. This observation challenges
existing drug development strategies for molecularly tar-
geted agents and raises the possibility of a shift towards
histology-agnostic molecularly-based treatment [5].
The mechanisms of cancer are marked by complex
aberrations in active and critical cellular signaling path-
ways involved in tumorigenesis [6]. The phosphoinositide
3-kinase (PI3K)-v akt murine thymoma viral oncogene
homolog (AKT)-mechanistic target of rapamycin (mTOR)
signaling cascade is one of the most important intracellu-
lar pathways that is frequently activated in diverse cancers
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[7, 8]. In many types of tumors, the activation of the PI3K-
AKT-mTOR pathway has been known as the relation to
tumorigenesis, cancer progression and the acquired resist-
ance to various anti-neoplastic agents [7, 9]. mTOR is an
evolutionarily conserved serine/threonine kinase which
acts downstream of the PI3K pathways. Thus, inhibition
of the mTOR pathway represents a novel therapeutic
strategy in the treatment of various cancers [10–13].
Everolimus, an mTOR inhibitor, demonstrates antipro-
liferative activity through the inhibition of the PI3K-
AKT-mTOR pathway and also has antiangiogenic
effects [14, 15]. Everolimus has shown antitumor activ-
ity in various types of tumors, but, it activity has lim-
ited in only a subset of cancer patients [11, 12, 16, 17].
However, there have not been predictive biomarkers for
everolimus, until now. Therefore, novel biomarkers are
needed to identify patients who would receive the most
benefit from everolimus treatment. Recently, in several
studies, PIK3CA/PTEN genomic aberrations have been
suggested to be strong predictors of everolimus sensi-
tivity [18–21]. PIK3CA amplifications and mutations
have been implicated in pathway activation and sensi-
tivity to mTOR inhibitors. Some preclinical models
have further shown that PTEN-deficient tumors present
an enhanced sensitivity to mTOR inhibitors because of
the sustained activation of PI3K-AKT signaling [22, 23].
These findings have enabled researchers to apply
mTOR inhibitors in many tumor-types with specific
genomic aberrations irrespective of tumor histology
and location.
We designed a single-arm, open-label phase II trial of
everolimus in PIK3CA amplification/mutation and/or
PTEN loss patients with advanced solid tumors refrac-
tory to standard therapy (#NCT02449538).
Methods
Eligibility
Patients were eligible if they had a histologically-confirmed
solid cancer with PTEN loss and/or PIK3CA amplifica-
tion/mutation. The additional case inclusion criteria were
as follows: (1) age over 18; (2) an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1; (3)
adequate bone marrow, liver, and renal function; (4) life
expectancy of at least 3 months. Patients who have an
acute active infection were not included in this study.
Patients who have any prior history of another malignancy
within 5 years of entry into the study, apart from nonmela-
noma skin cancer or carcinoma in situ of the uterine
cervix, were precluded participation in this study. In
addition, we did not include any patients with known brain
metastasis and concurrent uncontrolled hypertension,
symptomatic congestive heart failure, unstable angina pec-
toris, significant cardiac arrhythmia, or severe psychiatric
illness in this study. All patients provided written informed
consent according to the guidelines provided by the insti-
tutional review board and all procedures were carried out
according to guidelines from the Declaration of Helsinki.
The Institutional Review Board at Samsung Medical
Center approved the protocol.
PTEN loss was confirmed by immunohistochemistry
(IHC) test. Immunohistochemical staining was performed
on 3 um thick sections from each case on a BOND-MAX
autostainer (Leica, Melbourne, Australia) using BondTM
Polymer refine detection, DS9800 (Vision Biosystems,
Melbourne, Australia) after retrieval with T/E buffer. We
used primary antibodies to PTEN (1:100, Cellsignaling,
#9559). To evaluate the loss of PTEN expression, positive
staining of blood vessels and stromal cells were used as an
internal positive control. We classified the PTEN expres-
sion based on a four grading system: loss, weak positive
expression, moderate positive expression and strong posi-
tive expression with the later three categories being
lamped as the expression. PIK3CA amplification/mutation
was detected by targeted deep sequencing by CancerS-
CAN. Briefly, extracted genomic DNA was sheared to
150–200 bp using Covaris S220 (Covaris, Woburn, MA)
and targeted genes were captured using custom panel
capture library (Agilent Technologies, Santa Clara, CA)
for 2.5 Mb of exonic regions for Illumina Paired-End
Sequencing Library kit. We performed DNA sequencing
of 100 or 101-bp paired-end reads using the Illumina
HiSeq 2500 sequencer (Illumina, San Diego, CA).
Chemotherapy
Everolimus was administered orally at a daily dose of
10 mg continuously (28 day cycles). Treatment was
continued from day 1 until progression of the disease,
unacceptable toxicity, or the patient’s request. There-
after, the patients were followed up. Dose modification
was allowed in patients unable to tolerate the dosing
schedule defined by the protocol. If the toxicity was tol-
erable for the patient, the starting dose was maintained.
Dose reductions for toxicity were as follows: dose level
1, 5 mg daily; dose level 2, 5 mg every other day.
Assessment of efficacy and toxicity
Tumor response was routinely assessed with CT scan
every two cycles until the progression of disease. The re-
sponse was evaluated using a method identical to that
used in Response Evaluation Criteria in Solid Tumors
(RECIST) criteria, version 1.1. Toxicities were assessed
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE
version 4.0).
Statistical analysis
According to Simon’s two-stage optimal design, a sample
size of 23 was required to accept the hypothesis that the
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true RR is greater than 25% with 80% power, and to re-
ject the hypothesis that the RR is less than 5% with 5%
significance. In the first stage, if there was less than one
response out of the initial 10 patients, the study would
be terminated. Although the target number of patients
was 23, we planned to recruit 10% more than the target
number of patients due to expected dropout. Descriptive
statistics were reported as proportions and medians.
Kaplan–Meier estimates were used in the analysis of all
time-to event variables, and the 95% confidence interval
(CI) for the median time to event was computed.
Results
Patients
We screened total 82 patients with solid cancer between
April 2015 and December 2015. Among 82 patients, 29
patients had PIK3CA alterations or PTEN loss and then
10 patients were enrolled onto this study. These 10 pa-
tients were treated with everolimus in the first stage of
Simon’s two-stage optimal design. The median age of
the patients was 55.5 years (range, 42–72), and there
were 7 male and 3 female patients. Around half (50.0%)
of the patients had gastric cancer (GC) as the site of the
primary tumor followed by colorectal cancer (CRC),
pancreatic cancer and cholangiocarcinoma. Table 1
shows the baseline characteristics. The tumor samples of
nine patients were confirmed to show PTEN loss by
IHC and one GC with the PIK3CA mutation was found
by target sequencing (Table 2).
Response and survival
Response outcomes are listed in Table 3. Response
evaluation was conducted in the intent-to-treat popula-
tion. A complete or partial response was not observed in
any of the patients. Four patients showed stable disease
and 4 patients showed disease progression. The disease
stabilization rate was achieved in 40% of all patients.
The evaluation of treatment-response was not available
in two patients. All two patients were lost to follow-up
before the first response evaluation. All 10 patients were
included in survival analysis on an intent-to-treat basis.
The median PFS was 1.6 months (95% CI, 0.8–
2.4 months) (Fig. 1). Treatment was discontinued due to
disease progression in all enrolled patients. There was
less than one response out of the initial 10 patients
during the first stage, and the study did not continue
into the second stage.
Delivery of the drug and toxicity
The patients received a median of 1.7 (range, 1–4) cycles.
Dose reduction or treatment delay was not required in the
enrolled patients. Grade 3 or greater hematologic/non-
hematologic toxicity was not observed. Grade 2 diarrhea
Table 1 Baseline Characteristics of patients in this study
Characteristics No, of patients Percent
Age
Median (Range) 55.5 (42.0–72.0)
ECOG performance status







South Korea 10 100%
Disease Type
Gastric cancer 5 50%
Colorectal cancer 3 30%






Well differentiated 1 10%
Moderate differentiated 5 50%
Poorly differentiated 4 40%
Metastatic sites
Liver 4 40%
Lymph node 7 70%
Peritoneum 3 30%
No. of metastatic sites
≤ 1 7 70%
2 ≤ 3 30%





Table 2 The status of molecular markers in enrolled patients
Disease types Molecular markers
PTEN loss PIK3CA mutation/amplification
Gasric cancer 4 1
Colorectal cancer 3 -
Pancreastic cancer 1 -
Cholangiocarcinoma 1 -
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and stomatitis were reported in one patient each. There
were no treatment-related deaths.
Discussion
mTOR is a key down-stream protein kinase of the PI3K-
AKT signaling pathway, and everolimus is a novel macrolide
derivative of rapamycin that inhibits mTOR, thereby pre-
venting phosphorylation of its down-stream molecules. Its
promising antitumor effect has been reported in various
tumor types such as renal cell carcinoma, biliary tract cancer,
gastric cancer, and neuroendocrine tumor [10, 11, 13, 17].
PIK3CA/PTEN genomic aberrations have been suggested to
be strong predictors of everolimus sensitivity. In the
present study, we sought to investigate the anti-tumor
activity of everolimus in solid tumors with specific ge-
notypes such as PIK3CA amplification/mutation and/or
PTEN loss. However, this study did not meet the pri-
mary end point of the first stage of Simon’s two stage
design and was terminated without proceeding to the
second stage. To proceed to the stage, at least one pa-
tient with CR or PR was needed at the end of the first
stage of the study. Although there were four patients
with SD among the 10 patients enrolled in the first
stage, there was no CR or PR. Inconsistent findings
among clinical trials for everolimus may be caused by
heterogeneous patients’ population such as different
tumor-types, different races and etc.
mTOR is composed of two distinct protein complexes,
mTORC1 and mTORC2, that act on different levels of the
pathway [24, 25]. Unlike the mTORC1 complex, mTORC2
positively regulates cell survival and proliferation on differ-
ent signaling levels, mainly by phosphorylation as well as
through a serum and glucocorticoid inducible kinase [26].
Everolimus usually acts as an allosteric inhibitor of the
mTORC1 complex through interaction with FK-binding
protein 12 [27]. Thus, everolimus is generally thought to
have only weak activity against the mTORC2 complex,
which can lead to AKT activation [28]. This might have
affected the outcome of this study. Although this study se-
lected its subpopulation using specific genotypes that are
known as predictive markers for everolimus, mTOR sig-
naling via the mTORC2 complex could not be blocked.
Newly developed mTOR kinase blockades are expected
to provide a more robust inhibition of mTOR signaling
via suppression of both mTORC1 and mTORC2 com-
plexes. These agents are now in preclinical and clinical
trials and include TAK228/INK128, AZD8055, and AZ
D2014 [29–31]. We have also conducted phase II trial
using AZD2014 in gastric cancer (#NCT02449655).
Patients who achieved disease control with everolimus
had GC (n = 2), CRC (n = 1), and chonlangiocarcinoma
(n = 1). All of these patients had tumors with PTEN loss
and did not have other genomic aberrations such as
HER2 amplification, RAS mutation, and BRAF mutation
that might affect the PI3K-AKT-mTOR signaling. The
mTOR signaling pathway is linked to multiple levels of
feedbacks and diverse signal crosstalk. Although this
study used biomarker-driven patient selection, PTEN
loss and PIK3CA amplification/mutation alone were not
sufficient for predicting the anti-tumor activity of evero-
limus. Janku et al. reported various molecular aberration
including PIK3CA, PTEN, KRAS, NRAS, and BRAF in
1656 patients with PI3K/AKT/mTOR inhibitors [32].
Thus, more comprehensive molecular analysis will be
helpful to fully realize the potential of personalized
medicine using mTOR inhibitors including everolimus.
This study revealed that everolimus was tolerable in
heavily pretreated patients. Grade 3 or greater hematologic
and non-hematologic toxicity was not observed. Grade 2
diarrhea and stomatitis was reported in one patient each.
The 10 enrolled patients had already received many types
of cytotoxic chemotherapy before everolimus and most
had an ECOG PS of 2 (n = 9). Considering these charac-
teristics, everolimus was tolerable and safe.
Conclusion
The study did not meet its primary objective of demon-
strating the anti-tumor activity of everolimus in PIK3CA
Table 3 Treatment response of enrolled patients
Response No. of patients Percent
Complete response - -
Partial response 0 0%
Stable disease 4 40%
Progressive disease 4 40%
Not available 2 20%
Overall response rate 0%
Disease control rate 30%
Fig. 1 Progression free survival of enrolled patients
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amplification/mutation and/or PTEN loss patients with
advanced solid tumors refractory to standard therapy. A
greater understanding of the feedback mechanism and
crosstalk linked to the mTOR signaling-pathway is
needed. Further investigation using other potential gen-
omic candidates and next-generation mTOR inhibitors
is warranted in patients with refractory cancer.
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